SCHEMBL3477103

SCHEMBL3477103

O=C(O)NC1(Cc2ccccc2)CCOC1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HTT P42858 2/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
TSHR P16473 3/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
CYP3A4 P08684 2/20 0.34
MAPT P10636 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9834528 0.84 PPIA (0.46) ALDH1A1MEN1KMT2ATSHRMAPT
SCHEMBL28466349 0.80 ESR1 (0.36) ADRB2ALDH1A1HTTMEN1KMT2A
SCHEMBL377136 0.77 HTT (0.35) ADRB2ALDH1A1HTTMEN1KMT2A
SCHEMBL3530370 0.73 TOP2A (0.42) ALDH1A1HTTMEN1KMT2AL3MBTL1
SCHEMBL7714176 0.73 NAAA (0.39) ALDH1A1MEN1KMT2AL3MBTL1CYP2C9
SCHEMBL7619339 0.73 MAPK1 (0.37) ALDH1A1MEN1KMT2ATSHRL3MBTL1
SCHEMBL576279 0.73 L3MBTL1 (0.45) ALDH1A1HTTMEN1KMT2AL3MBTL1
Hydrochloric Acid SCHEMBL28211399 0.71 L3MBTL1 (0.44) HTTMEN1KMT2AL3MBTL1MAOA
SCHEMBL7353378 0.70 ELANE (0.40) MEN1KMT2ATSHRL3MBTL1MAOA
SCHEMBL10442397 0.70 MAOA (0.48) HTTMEN1KMT2AL3MBTL1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816378-B2 Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease MERCK SHARP & DOHME CORP. (US) 2010-10-19 US disclosed
US-20090176836-A1 Cyclic Ketal Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease MERCK SHARP & DOHME LLC 2009-07-09 US disclosed
EP-1912963-A2 CYCLIC KETAL BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Merck & Co., Inc. (US) 2008-04-23 EP disclosed
WO-2007019111-A2 CYCLIC KETAL BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176836-A1 Cyclic Ketal Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease BACE1, BACE2, PSEN1 ADRB2 2070/4885ALDH1A1 2290/4885HTT 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.